Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD) (NCT04169529), a registered phase not stated study. The primary outcome is COPD Event.

2. Clinical Question

These details set boundaries on what can be learned from the record. It identifies the population, device, and event of interest, but does not give a numerical estimate of the association between device-derived changes and COPD events. The endpoint wording refers to subject randomization as the start of its timeframe; that wording does not establish a randomized treatment allocation, which the record does not report.

3. Trial Design

The study, titled Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD), is recorded as completed. Its listed enrollment is 42. The registry gives a start date of 2020-08-25 and a primary completion date of 2023-06-27. Medtronic Cardiac Rhythm and Heart Failure is listed as the sponsor.

The intervention is Reveal LINQ, categorized in the record as a device. The stated purpose is to characterize data derived from Reveal LINQ in patients with COPD and assess the relationship between changes in those data and COPD exacerbation events. The record lists one outcome measure, whose primary endpoint is COPD Event: incidence of first COPD event, measured as a count of participants over the period from subject randomization until 12 month follow-up.

The registry record does not report an allocation scheme. It is identified as not being a randomized comparison, and the arms are not a like-for-like control comparison. No comparator is listed in the intervention information. Consequently, the record does not describe a controlled contrast from which to attribute a difference in event occurrence to one assigned treatment rather than another.

The listed enrollment should not be mistaken for the number contributing to every outcome or safety summary. The adverse-event information separately gives a full-cohort at-risk count of 40. The registry record does not explain the relationship between that count and the enrollment of 42, nor does it report the primary endpoint analysis population. It also does not provide detailed procedures for follow-up, monitoring, or data collection. The study status and dates describe its registry history, but do not fill in those design details.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Though 42 subjects were enrolled, 2 subjects did not have successful Reveal LINQ insertions. Therefore, 40 subjects started the study.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as COPD Event, measured over from subject randomization until 12 month follow-up.

The primary endpoint is the incidence of a first COPD event, reported as a count of participants. Its stated timeframe runs from subject randomization until 12 month follow-up. In plain terms, the endpoint is intended to record whether participants experienced a first event during the specified observation period, rather than to count repeated events for each participant.

A participant count is a binary-outcome summary: each participant is classified according to whether the event was recorded or not. General statistical context: counts can describe how many participants experienced an event, but interpretation also depends on the number included in the analysis and the completeness and duration of their observation. A count alone does not provide an event rate or a comparison between groups.

The endpoint is relevant to the stated study purpose because COPD exacerbation events are the clinical events whose relationship to changes in Reveal LINQ-derived data the study set out to assess. However, the registry record does not report the number of participants with a first COPD event, the number analyzed for this endpoint, or an estimate of the relationship with device-derived data. The endpoint definition explains what was intended to be counted; it does not itself establish the observed frequency or an association.

The registry uses the phrase subject randomization in describing the endpoint timeframe, but does not report randomized allocation. That wording should not be taken as evidence of a randomized comparison. The operational definition of a COPD event, including any adjudication or event criteria, is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a participant-count endpoint and a study purpose focused on the relationship between changes in Reveal LINQ-derived data and COPD exacerbation events. It lists one outcome measure and zero analyses. It does not report an analysis method, an endpoint result, an effect estimate, or an inferential statistic. General statistical explanations below clarify what such methods would mean, but they are not claims about methods used in this study.

What does a participant count represent?

The primary endpoint is a count of participants with a first COPD event over a stated follow-up period. For a binary endpoint, each participant contributes an event status: event recorded or not recorded. A count is directly interpretable only alongside the number of participants assessed and the rules used to determine event status. If participants have different amounts of observation or incomplete follow-up, a simple count can be difficult to interpret as a risk over a common period.

General statistical context: when comparing groups, analysts may summarize binary outcomes using quantities such as a difference in event proportions or a ratio of event proportions. These approaches require defined groups and enough information about each group’s event and non-event counts. No such comparison or endpoint counts are reported in the registry record. The study is not identified as a randomized comparison, and no comparator is listed, so a randomized group contrast cannot be inferred.

How should uncertainty be understood?

General statistical context: an estimate describes the pattern observed in a sample, while a confidence interval gives a range of values compatible with the data and the assumptions of the analysis. A narrow interval indicates greater precision than a wide interval, but neither an estimate nor its interval alone establishes causation. A p-value, when reported, addresses how compatible the data are with a specified null model; it does not measure the size or clinical importance of an association.

The registry record does not report a confidence interval, p-value, or other uncertainty measure for the primary endpoint or for the relationship between device-derived data and events. Thus, the precision of any primary finding cannot be assessed from the record. The count of analyses listed as zero is not a substitute for a null result or a statistical test.

What is over-dispersion?

General statistical context: over-dispersion occurs when observed variation in count data is greater than a model assumes. If a count model underestimates that variation, its uncertainty estimates may be too small and its intervals or tests may appear more precise than warranted. This issue is relevant to repeated event counts or other count outcomes when their variation exceeds a model’s assumptions. The primary endpoint recorded is a count of participants with a first event, not a reported total count of recurrent events. No model or dispersion assessment is described in the registry record, so it is not possible to say whether over-dispersion was assessed or relevant to any analysis actually conducted.

What does the planning illustration mean?

The planning assumptions describe an illustration based on the observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is framed as a stated fraction of the observed effect. These are planning assumptions, not a description of the trial’s own design or a reported sample-size justification. The record does not state that the study used equal allocation or a two-arm randomized comparison; indeed, it is identified as not being a randomized comparison and does not report allocation.

General statistical context: a planning calculation asks how many participants might be needed under chosen assumptions about an effect, variability, significance level, and desired power. It is not an observed result and does not show that a completed study had adequate power. The sample sizes from such calculations are illustrations, not observed power. The registry record does not report the protocol’s sample-size justification or confirm that these planning assumptions were used when the study was designed. No numerical planning results are stated in the registry record.

What analysis details are absent?

The registry record does not report a statistical analysis plan, a model for relating changes in device-derived data to COPD events, covariate adjustments, handling of repeated measurements, or a prespecified inferential procedure. It also does not describe whether outcomes were assessed at the participant level or using a time-to-event framework beyond the endpoint’s stated observation timeframe. These gaps prevent reconstruction of an analysis from the endpoint definition alone. In particular, the word incidence should not be taken to imply a rate model or survival analysis when no such method is reported.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Full Cohort")
n      <- c(40)
events <- c(28)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Full Cohort  40  28  70.0  53.5  83.4  54.6  81.9  54.5  81.9

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists one outcome measure and zero analyses. That inventory does not establish how many outcomes were considered in the study protocol, which outcomes were prespecified as primary, or whether additional analyses were conducted outside the registry results. The record does not report a multiplicity strategy, such as a method for controlling the risk of false-positive findings across multiple tests. A single listed outcome measure is not, by itself, evidence that no other analyses were planned or performed.

No endpoint result or analysis is reported for the primary COPD event measure. The registry record also does not describe a statistical analysis plan or identify a primary analysis population. The population field for the endpoint is blank. It therefore does not establish which enrolled participants were included in an endpoint analysis or how exclusions, withdrawals, or incomplete follow-up were handled.

Missing-data procedures are not reported in the registry record. The record does not say whether missing device-derived measurements or missing event-status information occurred, how missingness was assessed, or whether any imputation or sensitivity analysis was used. General statistical context: missing outcome information can affect an estimate if the participants with observed data differ systematically from those without it. The direction and size of any such effect depend on the data and assumptions; neither can be determined without information about missingness and the analysis.

These omissions matter because a numerical outcome estimate is interpretable only with a clear account of who contributed data and how incomplete observations were treated. The registry record does not provide that account. The listed enrollment of 42 and the full-cohort safety at-risk count of 40 do not resolve the analysis-population or missing-data questions for the primary endpoint.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: chronic obstructive pulmonary disease (47.5%), atrial fibrillation (12.5%), pneumonia (12.5%), chest pain (7.5%), anaemia (5.0%).

The registry reports safety figures for a group titled Full Cohort, with 40 participants at risk for serious adverse events and 40 at risk for other adverse events. Serious adverse events affected 27 participants; other adverse events affected 24 participants. The reported number of deaths is 4. These are descriptive counts, and the record does not provide a comparative analysis of safety between randomized arms.

The most frequently listed serious-event terms are chronic obstructive pulmonary disease at 47.5%, atrial fibrillation at 12.5%, pneumonia at 12.5%, chest pain at 7.5%, anaemia at 5.0%, and acute myocardial infarction at 5.0%. The record does not state the denominator or coding method for these percentages, so they should be read as registry-reported term percentages rather than converted into participant counts. It also does not report whether participants could contribute more than one event term.

The serious-event and other-event counts may overlap, and the record does not explain overlap or event attribution. It does not state whether events were considered related to Reveal LINQ, nor does it give a comparator suitable for estimating a relative safety difference. The reported deaths are a count; the registry record does not provide causes or an attribution assessment. These figures describe what is posted, not whether the device caused an event or how risks compare across treatments.

13. What the Result Does, and Does Not, Mean

The study’s stated aim is to characterize Reveal LINQ-derived data in people with COPD and assess the relationship between changes in those data and COPD exacerbation events. The registry identifies a primary endpoint—the incidence of a first COPD event, counted by participants over the stated follow-up timeframe—but does not report the endpoint count or an analysis of the relationship. The central study question therefore remains unquantified in the registry record.

The record does establish that 42 participants were enrolled and that the study is completed. It identifies the device intervention, sponsor, and dates, and it reports adverse-event summaries for a full cohort at risk of 40. Those details describe the registered study and posted safety information. They do not provide an estimate of how well device-derived data corresponded to events, how accurately changes identified events, or how uncertain any such estimate might be.

The record does not describe a randomized comparison or list a comparator. Thus, it cannot be read as a controlled comparison of the device against an alternative. More generally, an observed association between a device-derived measure and an event, if reported, would not on its own show that the measure caused the event. It also would not establish that using the measure to guide decisions changes outcomes. No such association analysis is reported.

The safety counts and term percentages should likewise be interpreted descriptively. The record does not state whether adverse events were attributed to the device, and the figures do not establish a comparative safety effect. Absence of an endpoint analysis in the registry is not evidence that no events occurred or that no relationship exists. It means the posted record does not provide results needed to assess the primary question.

In short, the registry supports understanding the study’s purpose, endpoint definition, enrollment, and selected safety summaries. It does not support a conclusion about the magnitude, precision, predictive performance, or cause-and-effect meaning of a relationship between Reveal LINQ-derived data and COPD events.

14. Why This Trial Matters Statistically

This study is statistically notable because it asks about the relationship between changes in device-derived data and a clinical event, rather than presenting a randomized treatment comparison. The distinction matters: a descriptive or associational analysis addresses whether measurements and events vary together, while a randomized comparison is designed to estimate differences between assigned groups under its design assumptions. The registry identifies this study as not being a randomized comparison and does not list a comparator.

The primary endpoint also illustrates why an outcome definition and an outcome result are different things. The record specifies a first COPD event counted among participants over a stated follow-up period, but does not report the number of participants with such an event or an analysis connecting events with device-derived changes. Without an estimate and a measure of uncertainty, readers cannot assess the size or precision of the proposed association. The endpoint definition alone cannot answer the study’s main question.

The registry’s safety summary is another reminder that counts need context. The full cohort safety at-risk count is 40, while enrollment is 42. The record does not explain that difference, and the at-risk number for safety should not automatically be treated as the endpoint analysis population. Clear reporting of analysis populations, event definitions, missing-data handling, and statistical methods is important for understanding what each count represents.

Finally, planning calculations and observed findings serve different purposes. The recorded planning assumptions describe an illustration rather than the trial’s own sample-size justification. Such calculations cannot replace a reported endpoint estimate, and they are not observed power. The absence of a reported analysis makes these distinctions especially important: the record gives useful study context, but not the numerical findings required to judge the primary statistical question.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation in interpreting the registry record is that it does not report a primary endpoint result or an analysis of the relationship between changes in Reveal LINQ-derived data and COPD events. The number of participants with a first COPD event, the number included in that analysis, and any estimate of association are not reported in the registry record. There is therefore no basis in the posted results for assessing magnitude or precision.

The design information is limited. The record states that this was not a randomized comparison and does not state allocation or identify a comparator. The endpoint timeframe refers to subject randomization, but the record does not explain that wording in relation to the study design. It also does not report detailed eligibility criteria, event adjudication procedures, or the specific device-derived measures evaluated.

The registry records enrollment of 42, but its safety summary gives an at-risk cohort of 40. It does not explain the difference, and it does not report whether the primary endpoint analysis included the same participants. The outcome population field is blank. Follow-up completeness, withdrawals, missing data, and procedures for handling incomplete observations are not reported.

Statistical methods are also not described. The record lists zero analyses and does not provide an analysis plan, model, covariate strategy, uncertainty estimates, or multiplicity procedures. The planning assumptions are identified as an illustration rather than the study’s design justification, and the registry does not say that they governed the trial. For safety, the record does not report event attribution, causes of death, or the denominator and coding details for the term percentages. These limits constrain interpretation of both efficacy-related outcomes and safety summaries.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD) — NCT04169529.
• Registry record last updated 2024-10-26; status last verified 2024-10.
• Results first posted 2024-10-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes the completed Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD) study, sponsored by Medtronic Cardiac Rhythm and Heart Failure. Enrollment is 42, and the recorded dates are 2020-08-25 for study start and 2023-06-27 for primary completion. The stated purpose is to characterize Reveal LINQ-derived data in people with COPD and assess their relationship to COPD exacerbation events.

The primary endpoint is the incidence of a first COPD event, counted among participants from subject randomization until 12 month follow-up. The record lists one outcome measure and zero analyses, and does not report the endpoint count or an analysis of the study question. It identifies the study as not being a randomized comparison and does not state allocation or list a comparator.

Safety information gives a full-cohort at-risk count of 40, with 27 participants affected by serious adverse events, 24 by other adverse events, and 4 deaths. These summaries are descriptive; the record does not provide device attribution or a comparative safety analysis. The registry provides study context, but not a numerical answer to its primary statistical question.